Sign In To Continue
You have reached the guest article limit.
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
Aethlon Medical, a clinical-stage company developing therapies for cancer and viral infections, announced fiscal year 2026 financial results and key corporate developments. The company progressed to the third dosing cohort in its Australian oncology trial, expanded intellectual property protections for the Hemopurifie…
Share This Article
Ready-to-post copy includes the article link.
Aethlon Medical Advances Australian Oncology Trial and Expands Hemopurifier Patent Portfolio Through Fiscal Year 2026 Aethlon Medical, a clinical-stage company developing therapies for cancer and viral infections, announced fiscal year 2026 financial results and key corporate developments. The company progressed to the third dosing coh... Read the full IIPLA article: https://iipla.org/news/aethlon-medical-advances-australian-oncology-trial-and-expands-hemopurifier-patent-portfolio-through-fiscal-year-2026